Effect of Acorus calamus L. Polysaccharide on CD274 and CD326 Expression by Lewis Lung Carcinoma Cells in Mice


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Tumor cells can maintain their growth via immunosuppression and escape from host antitumor immunity by controlling the PD-1/PD-L1 system. Expression of PD-L1 (CD274) is an inhibitory signal for T cells, while the increase in CD326 expression in the tumor tissue correlates with metastasis development. The experimental preparation on the basis of α(1,2)-L-rhamno-α(1,4)-D-galactopyranosyluronan from Acorus calamus L. produces an antitumor effect: it reduces tumor node size and the number and area of metastases after transplantation of Lewis lung carcinoma. Using flow cytometry, we demonstrated a decrease in the population of tumor cells expressing surface CD274 (PD-L1) and CD326 antigens after 20-day course of α(1,2)-L-rhamno-α(1,4)-D-galactopyranosyluronan.

About the authors

K. A. Lopatina

Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center; Laboratory of Phytochemistry of Siberian Botanical Garden of National Research Tomsk State University

Author for correspondence.
Email: k.lopatina@pharmso.ru
Russian Federation, Tomsk; Tomsk

E. A. Safonova

Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: k.lopatina@pharmso.ru
Russian Federation, Tomsk

K. V. Nevskaya

Department of Pharmaceutical Analysis, Centre for Introduction of Technologies, Siberian State Medical University, Ministry of Health of the Russian Federation

Email: k.lopatina@pharmso.ru
Russian Federation, Tomsk

M. N. Stakheeva

Laboratory of Molecular Oncology and Immunology, Research Institute of Oncology, Tomsk National Research Medical Center

Email: k.lopatina@pharmso.ru
Russian Federation, Tomsk

A. M. Gur’ev

Department of Pharmaceutical Analysis, Centre for Introduction of Technologies, Siberian State Medical University, Ministry of Health of the Russian Federation

Email: k.lopatina@pharmso.ru
Russian Federation, Tomsk

E. P. Zueva

Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: k.lopatina@pharmso.ru
Russian Federation, Tomsk

T. G. Razina

Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: k.lopatina@pharmso.ru
Russian Federation, Tomsk

E. N. Amosova

Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: k.lopatina@pharmso.ru
Russian Federation, Tomsk

S. G. Krylov

Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: k.lopatina@pharmso.ru
Russian Federation, Tomsk

M. V. Belousov

Department of Pharmaceutical Analysis, Centre for Introduction of Technologies, Siberian State Medical University, Ministry of Health of the Russian Federation

Email: k.lopatina@pharmso.ru
Russian Federation, Tomsk


Copyright (c) 2017 Springer Science+Business Media, LLC, part of Springer Nature

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies